Form 4: BioXcel Therapeutics CEO Vimal Mehta Reports Stock Sales and RSU Transactions
SEC Form 4
BioXcel Therapeutics CEO Vimal Mehta reported the sale of common stock and the vesting of restricted stock units (RSUs) in recent transactions.
Summary
- Vimal Mehta, CEO and President of BioXcel Therapeutics, reported transactions involving the company's common stock and restricted stock units.
- On March 14, 2024, and March 15, 2024, Mehta exercised options on 2,610 and 14,000 shares respectively.
- On April 4, 2024, Mehta sold 829 shares at $2.62 and 4,439 shares at a weighted average price of $2.6247.
- Following these transactions, Mehta directly owns 43,564 shares of common stock.
- Mehta also indirectly owns 2,000 shares through his spouse and 8,546,750 shares through BioXcel LLC.
- The sales on April 4, 2024, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an insider, with no inherent positive or negative sentiment.
Management Comments
- The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies.
Stakeholder Impact
- The stock sales by the CEO could be perceived negatively by some shareholders, although the sales were conducted under a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| March 14, 2022 | Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| March 15, 2023 | Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| December 14, 2023 | Reporting Person adopted a Rule 10b5-1 trading plan. |
| March 14, 2024 | CEO exercised options on 2,610 shares. |
| March 15, 2024 | CEO exercised options on 14,000 shares. |
| April 04, 2024 | CEO sold 829 shares at $2.62 and 4,439 shares at a weighted average price of $2.6247. |
| April 08, 2024 | Date of report. |
Keywords
BioXcel Therapeutics, BTAI, Vimal Mehta, Stock Sale, RSU, Form 4, Insider Trading, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.